Benefits of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

Castillo, Nathalie Torres del; Paredes, Luisa Talledo; Shek, Nathaly; Gutiérrez, Hugo Hurtado; Betancourt-Peña, Jhonatan

doi:10.1016/j.chest.2017.08.1018

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies compared nonpharmacological complex interventions with usual care [ 2 , 26 , 38 ]. Among 22 studies that assessed PR or exercise training, one study compared PR in participants with IPF to PR in those with other ILD diagnoses [ 54 ], while another study compared PR in participants with IPF with those with sarcoidosis [ 31 ]. One study compared PR in participants with IPF with PR in those with COPD from a previous study [ 58 ].…”

Section: Resultsmentioning

confidence: 99%

“…No significant improvement was found on longer follow-up. Five of these studies [ 30 , 36 , 44 , 54 , 56 ] found a statistically significant improvement in dyspnoea immediately after the intervention but did not assess its long-term sustainability. C hehere et al [ 55 ] used one unidimensional (Borg scale) [ 86 ] and one multidimensional (BDI/TDI) [ 90 ] method to assess dyspnoea and found contrasting results: results from the BDI/TDI showed significant improvement while that with the Borg scale was not significant.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis

Colquitt¹,

Loveman²,

Bausewein³

et al. 2020

ERJ Open Res

View full text Add to dashboard Cite

We assessed efficacy and effectiveness of pharmacological and non-pharmacological interventions in improving symptom control, functional exercise capacity and quality of life (Qol) in people living with fibrotic interstitial lung disease (ILD).We summarised evidence from three previous reviews (to June 2014) and conducted an updated search of nine databases and grey literature (2011–19) (registration: CRD42017065933) for prospective studies of interventions aimed to alleviate symptoms, improve Qol or functional exercise capacity in fibrotic ILD. Data were synthesised through narrative synthesis or meta-analysed as appropriate.Forty-seven studies with 2527 participants were included. From 22 pharmacological studies of eleven different interventions (n=1683) the most tested interventions were bosentan and sildenafil. From 25 non-pharmacological studies, the most tested intervention was for pulmonary rehabilitation / exercise training (PR) (22 studies, n=748). An improvement in 6-min walk distance (6MWD) immediately following PR (6 studies; n=200, MD [95%CI] 39.9 m [18.2 to 61.5]) but not longer-term (3 or 6 months, 4 studies; n=147, MD 5.3 m [−12.9 to 23.4]. Multiple, varied outcome measures were used, e.g. 37 studies assessing dyspnoea used 10 different scales with lack of reporting of rate of deterioration in outcomes. Evidence gap mapping highlighted the most and least researched symptoms were dyspnoea and cough respectively.This evidence synthesis highlights overwhelmingly that the most researched symptom is dyspnoea and the strongest evidence base is for short-term PR. The least researched symptom was cough. Research going forward must focus on prioritising and standardising meaningful outcomes and focusing interventions on neglected symptoms.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis

Colquitt¹,

Loveman²,

Bausewein³

et al. 2020

ERJ Open Res

View full text Add to dashboard Cite

show abstract

Pulmonary Rehabilitation in COVID-19: The Contribution of other Chronic Lung Syndromes for the Intervention of a Novel Disease

Benavides-Cordoba

Diana

Betancourt-Peña

2021

CRMR

View full text Add to dashboard Cite

COVID-19 has spread throughout the world causing a significant number of cases of pneumonia and SARS. Patients with COVID-19 may also have other cardiovascular, respiratory, and neuromuscular disorders. These multisystemic complications present the need for comprehensive interventions focused on improving symptoms, functional capacity, and quality of life. Pulmonary rehabilitation has the potential to offer some of these benefits. However, the evidence related to specific aspects of pulmonary rehabilitation evaluation and intervention in COVID19 is limited. We have learned from experiences with other types of chronic lung diseases that have used pulmonary rehabilitation successfully, so that while the own evidence of rehabilitation emerges in COVID-19, it is necessary to establish some initial recommendations, prepared according to the sequelae found until now.

show abstract

Benefits of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

Cited by 2 publications

References 0 publications

Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis

Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis

Pulmonary Rehabilitation in COVID-19: The Contribution of other Chronic Lung Syndromes for the Intervention of a Novel Disease

Contact Info

Product

Resources

About